Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.27)
# 3,476
Out of 4,876 analysts
112
Total ratings
33.68%
Success rate
-12.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $8 → $8.5 | $9.21 | -7.66% | 6 | Jun 17, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.12 | +701.89% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $125.66 | +27.33% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $126.83 | +73.46% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $7.09 | +196.19% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $9.11 | +174.42% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $2.96 | +305.41% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $2.77 | +441.52% | 3 | Feb 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $8.59 | +749.83% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.92 | +4,066.67% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.40 | +125.81% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $2.24 | +391.07% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.98 | +1,986.79% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $6.74 | +107.72% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $11.83 | +69.13% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.09 | +49.39% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $14.69 | +921.10% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.69 | - | 2 | Jan 31, 2017 |
Sage Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $8 → $8.5
Current: $9.21
Upside: -7.66%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.12
Upside: +701.89%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $125.66
Upside: +27.33%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $126.83
Upside: +73.46%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $7.09
Upside: +196.19%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $9.11
Upside: +174.42%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $2.96
Upside: +305.41%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $2.77
Upside: +441.52%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $8.59
Upside: +749.83%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.92
Upside: +4,066.67%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.40
Upside: +125.81%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $2.24
Upside: +391.07%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.98
Upside: +1,986.79%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $6.74
Upside: +107.72%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.83
Upside: +69.13%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.09
Upside: +49.39%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $14.69
Upside: +921.10%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.69
Upside: -